Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Simvastatin has no therapeutic benefit in COPD, researchers conclude

Man with oxygen mask (Wonderwolf/

Time to exacerbation was similar in the placebo and statin groups

Simvastatin does not prevent exacerbations in people with moderate-to-severe chronic obstructive pulmonary disease (COPD), suggest results of a large prospective randomised placebo-controlled trial reported in The New England Journal of Medicine.

Treatment with the statin also failed to impact lung function, quality of life, severe adverse events or mortality, leading the researchers to conclude that their data “did not show a therapeutic benefit of statins in patients with moderate-to-severe COPD”.

Several previous studies have reported benefits of statin therapy in patients with COPD but all but one have been retrospective. The STATCOPE trial was undertaken to test this hypothesis in a prospective, controlled manner. It included 885 patients aged 40–80 years with COPD and a smoking history of at least 10 pack-years (calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked) who were considered to be at high risk for exacerbations. 

Study participants were randomly assigned to receive simvastatin 40mg or placebo once daily and treated for a mean of 639 and 641 days, respectively. During this time there were 1,982 acute COPD exacerbations. Rates were similar in the simvastatin and placebo groups, at 1.36 and 1.39 exacerbations per person–year, respectively (P=0.54).

The median time to first exacerbation was similar between treatment groups, as was the number of non-fatal serious adverse events and deaths. Simvastatin had no effect on lung function, assessed using spirometry, or on general or respiratory-specific quality of life. As expected, levels of low-density lipoprotein cholesterol showed a greater decline over the study period in the simvastatin group than the placebo group.

The STATCOPE investigators conclude that daily use of 40mg simvastatin, in addition to usual care, “has no role in preventing exacerbations in moderate-to-severe COPD”. “The underuse of statins in persons with cardiac risk factors who have been included in retrospective studies may account in part for the differences between our findings and those previously reported,” they suggest.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.11138501

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Essentials of Economic Evaluation in Healthcare

    Essentials of Economic Evaluation in Healthcare

    An introduction to economic evaluation specific to healthcare, for those with little or no knowledge of economics. Covers cost effectiveness, cost utility and cost benefit analysis.

    £33.00Buy now
  • International Research in Healthcare

    International Research in Healthcare

    Guidance for students or researchers undertaking a multi-centre research project in health services, medicines use and professional practice.

    £38.00Buy now
  • Chronotherapeutics


    Chronotherapeutics discusses the pharmaceutical and therapeutic implications associated with biological clocks in humans.

    £38.00Buy now
  • Disease Management

    Disease Management

    Disease Management covers the diseases commonly encountered in primary care by system, with common therapeutic issues. Includes case studies and self-assessment sections.

    £54.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.